117 results about "Immune reactivity" patented technology

The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and / or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and / or single-stranded run-on mRNAs.

Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.

Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and / or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.

The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human SIRPα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function.

The invention discloses an immune chromatography test paper strip based on an up-conversion luminescence technology. The up-conversion luminescence material, i.e. UCP, is used as a biological marker, and the result can be presented in a visible light signal form under the radiation of infrared light and can be interpreted by an instrument, thereby quantitative detection on the target detected object is realized. The test paper strip mainly comprises a sample pad, a binding pad or a binder release pad, an analyzing membrane, a water absorbing pad and a plastic back plate. The invention also discloses a method for preparing the test paper strip, and application in the biological sample quantitative detection. According to different immune reaction modes of the substances to be detected, the test paper strip is classified according to a sandwich mode, a competition mode and an indirection mode, and various modes of the test paper strips can carry out quick and sensitive qualitative and quantitative detection and analysis on different substances to be detected in the sample.

The invention discloses a method for obtaining a tumor specific T cell receptor. The method comprises the following steps: firstly, obtaining a T cell receptor gene sequence in an antigen peptide specific T cell which comes from an immunoreactive positive and / or tumor symptom relieved tumor patient after antigen peptide treatment; then, preparing an antigen specific T cell receptor according to the antigen specific T cell receptor gene sequence; introducing the antigen peptide specific T cell receptor gene into the T cell, and expressing the antigen peptide specific T cell receptor gene to obtain the specific TCR-T cell. The specific TCR-T cell can be used for successfully killing gene mutation corresponding to antigen peptide and HLA typed tumor cell, and has high killing efficiency and agood application prospect.

Methods for the detection, monitoring and treatment of malignancies in which the HER-2 / neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2 / neu protein, or detection of immunocomplexes formed between the HER-2 / neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2 / neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”). The diabodies of the present invention are capable of simultaneously binding to PD-1 and to LAG-3, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such diabodies, and to methods involving the use of such diabodies in the treatment of cancer and other diseases and conditions.

The present invention relates generally to a diagnostic assay and, more particularly, an assay for measuring cell-mediated immune reactivity. Even more particularly, the present invention provides an assay and a kit for measuring a cell-mediated response to an antigen using whole blood or other suitable biological sample. The assay may be conducted using ligands to immune effector molecules or at the nucleic acid level, screening for expression of genes encoding the immune effector molecules. The assay is useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications.

An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and / or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and / or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and / or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and / or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and / or prevention of cancer comprising the same as an active ingredient.

Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.

Immune-chips, which are arrays of peptides probes are used to obtain a pattern which characterizes the global immune reactivity status of the human or other organism, are described. The peptide probes participate in immune reactions with antibodies and immune receptors of the investigated organisms to generate an immune pattern on the chip, which are detected and stored as patterns in databases. The patterns are then compared with other patterns observed with the same array and obtained under physiological, pathological and experimental conditions from the same or other organisms. The comparison is used to classify the state of the investigated organisms based on similarity to other observed states. The immune chips and the obtained patterns can be used for clinical diagnosis and biological studies, such as the investigation of similarities between physiological, pathological or experimental processes.

Compounds and compositions for eliciting or enhancing immune reactivity to HER-2 / neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2 / neu oncogene is associated.

Oligonucleotides containing the non-palindromic sequence motif: X1X2X3X4X5X6X7X8, wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.

The invention relates to a nanometer microsphere or a nanometer hollow sphere of casein or casein-polyacrylic acid compound, and a nanometer microsphere or a nanometer hollow sphere of cross-linking casein, wherein the nanometer microsphere or the nanometer hollow sphere of the casein or casein-polyacrylic acid compound consists of a compound of casein and polyacrylic acid, and the average grain diameter of the nanometer microsphere or the nanometer hollow sphere is 170-370nm; the nanometer microsphere or the nanometer hollow sphere of cross-linking casein consists of cross-linking casein, andthe average grain diameter of the nanometer microsphere or the nanometer hollow sphere is 240-500nm. The nanometer microsphere or the nanometer hollow sphere of cross-linking casein has good biocompatibility and biodegradability without causing organism immunoreaction; degradation products of the nanometer microsphere or the nanometer hollow sphere of cross-linking casein can be absorbed and metabolized by a human body and has the treatment action, nutritive efficiency and the like on the human body, and therefore, the nanometer microsphere or the nanometer hollow sphere of cross-linking casein can be used as a carrier of drugs. The invention discloses a preparation method of the nanometer microsphere or the nanometer hollow sphere of the casein or casein-polyacrylic acid compound, and apreparation method of the nanometer microsphere or the nanometer hollow sphere of cross-linking casein.